Our study adds to emerging data that further clarify the mechanisms of action of tranylcypromine-derivative LSD1 inhibitors such as iadademstat and bomedemstat which are currently being evaluated for efficacy alone or in combination in diverse malignancies such as AML, myelofibrosis and essential thrombocythemia [4, 40]. This evidence concerns the gene KDM1A and essential thrombocythemia.